Altimmune Current Deferred Revenue vs Capital Surpluse Analysis

ALT Stock

USD 8.25 0.07 0.86%

Altimmune financial indicator trend analysis is way more than just evaluating Altimmune prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Altimmune is a good investment. Please check the relationship between Altimmune Current Deferred Revenue and its Capital Surpluse accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

Current Deferred Revenue vs Capital Surpluse

Current Deferred Revenue vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Altimmune Current Deferred Revenue account and Capital Surpluse. At this time, the significance of the direction appears to have very week relationship.

The correlation between Altimmune's Current Deferred Revenue and Capital Surpluse is 0.26. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Altimmune, assuming nothing else is changed. The correlation between historical values of Altimmune's Current Deferred Revenue and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Altimmune are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Current Deferred Revenue i.e., Altimmune's Current Deferred Revenue and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.26

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Capital Surpluse

Most indicators from Altimmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 44.70 in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (5.02).

	2021	2022	2023	2024 (projected)
Research Development	74.5M	70.5M	65.8M	69.1M
Depreciation And Amortization	551.3K	500K	477K	435.7K

Research Development Depreciation And Amortization

Altimmune fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Other Assets	Non Current Liabilities Total	Short Term Debt	Short Long Term Debt Total	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Short Term Investments
Total Assets		0.4	0.43	0.85	-0.94	-0.42	0.46	0.94	0.98	0.08	0.78	0.37	0.65	0.45	0.99	0.2	0.19	-0.12	0.02	-0.25	-0.24	0.05	0.01	0.47	0.18	0.81
Other Current Liab	0.4		1.0	-0.14	-0.44	0.3	-0.01	0.43	0.45	0.39	-0.12	-0.08	-0.26	1.0	0.42	0.35	-0.11	-0.1	-0.29	0.24	-0.12	-0.22	-0.19	0.93	-0.29	0.37
Total Current Liabilities	0.43	1.0		-0.11	-0.48	0.27	0.03	0.47	0.48	0.41	-0.09	-0.03	-0.22	1.0	0.45	0.36	-0.06	-0.12	-0.31	0.25	-0.13	-0.23	-0.2	0.94	-0.3	0.36
Total Stockholder Equity	0.85	-0.14	-0.11		-0.75	-0.64	0.49	0.76	0.8	-0.15	0.91	0.42	0.85	-0.09	0.83	0.01	0.26	-0.05	0.19	-0.42	-0.18	0.2	0.1	-0.04	0.35	0.68
Net Debt	-0.94	-0.44	-0.48	-0.75		0.48	-0.49	-1.0	-0.95	-0.25	-0.75	-0.55	-0.64	-0.48	-0.94	-0.35	-0.42	0.25	0.25	0.14	0.37	0.12	0.1	-0.55	-0.04	-0.62
Retained Earnings	-0.42	0.3	0.27	-0.64	0.48		-0.67	-0.5	-0.5	-0.3	-0.84	-0.15	-0.94	0.26	-0.45	-0.47	-0.13	0.43	0.29	0.03	0.55	0.31	0.33	0.28	0.07	-0.31
Accounts Payable	0.46	-0.01	0.03	0.49	-0.49	-0.67		0.49	0.49	0.26	0.63	0.16	0.64	0.03	0.47	0.4	0.18	-0.27	-0.22	0.18	-0.32	-0.22	-0.15	0.15	-0.09	0.33
Cash	0.94	0.43	0.47	0.76	-1.0	-0.5	0.49		0.96	0.25	0.76	0.54	0.66	0.48	0.94	0.34	0.41	-0.26	-0.25	-0.14	-0.38	-0.12	-0.12	0.53	0.04	0.63
Cash And Short Term Investments	0.98	0.45	0.48	0.8	-0.95	-0.5	0.49	0.96		0.22	0.78	0.34	0.68	0.49	0.98	0.34	0.17	-0.26	-0.16	-0.15	-0.38	-0.1	-0.12	0.49	0.08	0.82
Common Stock Total Equity	0.08	0.39	0.41	-0.15	-0.25	-0.3	0.26	0.25	0.22		-0.02	-0.01	0.13	0.4	0.14	0.95	0.06	-0.42	-0.65	0.51	-0.45	-0.61	-0.62	0.31	-0.36	-0.01
Common Stock Shares Outstanding	0.78	-0.12	-0.09	0.91	-0.75	-0.84	0.63	0.76	0.78	-0.02		0.33	0.95	-0.07	0.78	0.18	0.22	-0.2	0.0	-0.3	-0.34	0.02	-0.07	-0.03	0.08	0.6
Other Current Assets	0.37	-0.08	-0.03	0.42	-0.55	-0.15	0.16	0.54	0.34	-0.01	0.33		0.27	-0.04	0.34	-0.05	0.96	-0.08	-0.18	-0.15	-0.09	0.05	0.17	0.2	0.16	-0.15
Other Stockholder Equity	0.65	-0.26	-0.22	0.85	-0.64	-0.94	0.64	0.66	0.68	0.13	0.95	0.27		-0.21	0.66	0.31	0.18	-0.31	-0.11	-0.2	-0.44	-0.12	-0.19	-0.21	0.1	0.5
Total Liab	0.45	1.0	1.0	-0.09	-0.48	0.26	0.03	0.48	0.49	0.4	-0.07	-0.04	-0.21		0.46	0.35	-0.08	-0.14	-0.29	0.24	-0.15	-0.24	-0.16	0.94	-0.26	0.39
Total Current Assets	0.99	0.42	0.45	0.83	-0.94	-0.45	0.47	0.94	0.98	0.14	0.78	0.34	0.66	0.46		0.26	0.18	-0.09	-0.02	-0.2	-0.22	0.07	-0.1	0.47	0.13	0.81
Common Stock	0.2	0.35	0.36	0.01	-0.35	-0.47	0.4	0.34	0.34	0.95	0.18	-0.05	0.31	0.35	0.26		0.01	-0.42	-0.6	0.43	-0.48	-0.58	-0.63	0.26	-0.36	0.12
Current Deferred Revenue	0.19	-0.11	-0.06	0.26	-0.42	-0.13	0.18	0.41	0.17	0.06	0.22	0.96	0.18	-0.08	0.18	0.01		-0.05	-0.24	0.02	-0.04	0.02	0.07	0.17	0.09	-0.35
Other Assets	-0.12	-0.1	-0.12	-0.05	0.25	0.43	-0.27	-0.26	-0.26	-0.42	-0.2	-0.08	-0.31	-0.14	-0.09	-0.42	-0.05		0.7	-0.24	0.97	0.93	-0.03	-0.05	0.04	-0.13
Non Current Liabilities Total	0.02	-0.29	-0.31	0.19	0.25	0.29	-0.22	-0.25	-0.16	-0.65	0.0	-0.18	-0.11	-0.29	-0.02	-0.6	-0.24	0.7		-0.38	0.74	0.74	0.49	-0.27	0.51	0.09
Short Term Debt	-0.25	0.24	0.25	-0.42	0.14	0.03	0.18	-0.14	-0.15	0.51	-0.3	-0.15	-0.2	0.24	-0.2	0.43	0.02	-0.24	-0.38		-0.13	-0.38	-0.48	0.14	-0.01	-0.23
Short Long Term Debt Total	-0.24	-0.12	-0.13	-0.18	0.37	0.55	-0.32	-0.38	-0.38	-0.45	-0.34	-0.09	-0.44	-0.15	-0.22	-0.48	-0.04	0.97	0.74	-0.13		0.88	0.08	-0.06	0.16	-0.25
Property Plant And Equipment Net	0.05	-0.22	-0.23	0.2	0.12	0.31	-0.22	-0.12	-0.1	-0.61	0.02	0.05	-0.12	-0.24	0.07	-0.58	0.02	0.93	0.74	-0.38	0.88		0.07	-0.14	0.18	0.05
Non Current Assets Total	0.01	-0.19	-0.2	0.1	0.1	0.33	-0.15	-0.12	-0.12	-0.62	-0.07	0.17	-0.19	-0.16	-0.1	-0.63	0.07	-0.03	0.49	-0.48	0.08	0.07		-0.05	0.48	-0.04
Non Currrent Assets Other	0.47	0.93	0.94	-0.04	-0.55	0.28	0.15	0.53	0.49	0.31	-0.03	0.2	-0.21	0.94	0.47	0.26	0.17	-0.05	-0.27	0.14	-0.06	-0.14	-0.05		-0.3	0.28
Net Receivables	0.18	-0.29	-0.3	0.35	-0.04	0.07	-0.09	0.04	0.08	-0.36	0.08	0.16	0.1	-0.26	0.13	-0.36	0.09	0.04	0.51	-0.01	0.16	0.18	0.48	-0.3		0.15
Short Term Investments	0.81	0.37	0.36	0.68	-0.62	-0.31	0.33	0.63	0.82	-0.01	0.6	-0.15	0.5	0.39	0.81	0.12	-0.35	-0.13	0.09	-0.23	-0.25	0.05	-0.04	0.28	0.15

Click cells to compare fundamentals

Altimmune Account Relationship Matchups

Altimmune fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	54.1M	245.1M	218.9M	206.9M	210.6M	221.2M
Other Current Liab	3.6M	11.0M	6.1M	10.6M	9.6M	17.0M
Total Current Liabilities	3.9M	12.0M	18.3M	17.1M	12.1M	21.2M
Total Stockholder Equity	45.5M	225.9M	199.1M	185.3M	194.1M	203.8M
Net Debt	(7.2M)	(114.1M)	(188.8M)	(110.0M)	(134.4M)	(127.7M)
Retained Earnings	(137.4M)	(186.4M)	(293.2M)	(377.9M)	(466.3M)	(443.0M)
Accounts Payable	18.2K	612.3K	2.0M	4.8M	2.1M	1.5M
Cash	9.0M	115.9M	190.3M	111.1M	135.1M	141.9M
Cash And Short Term Investments	37.2M	215.9M	190.3M	184.9M	197.8M	207.7M
Common Stock Total Equity	876.0	1.5K	3.7K	4.1K	4.7K	3.9K
Common Stock Shares Outstanding	13.1M	25.6M	41.3M	46.9M	53.2M	55.9M
Liabilities And Stockholders Equity	54.1M	245.1M	218.9M	206.9M	210.6M	221.2M
Other Current Assets	504.4M	2.0B	13.4B	5.4M	7.0M	6.6M
Other Stockholder Equity	187.9M	417.3M	497.3M	568.4M	665.4M	698.7M
Total Liab	8.5M	19.2M	19.7M	21.6M	16.5M	27.3M
Total Current Assets	39.4M	230.3M	204.1M	192.8M	209.6M	220.1M
Common Stock	1.5K	3.7K	4.1K	5K	7K	4.2K
Other Assets	128.5K	977.2K	73.8K	19K	1.0	0.95
Non Current Liabilities Total	4.6M	7.2M	1.5M	4.6M	4.4M	4.7M
Short Term Debt	259.4K	356.7K	411.5K	452K	496K	471.2K
Short Long Term Debt Total	2.1M	2.2M	1.9M	1.1M	671K	637.5K
Property Plant And Equipment Net	1.8M	2.0M	1.4M	1.1M	1.0M	1.5M
Non Current Assets Total	14.7M	14.9M	14.7M	14.1M	1.0M	963.3K
Non Currrent Assets Other	128.5K	73.4K	872.0K	615K	100.0K	95.0K
Net Receivables	1.7M	12.4M	5.8M	2.5M	4.9M	5.0M
Property Plant And Equipment Gross	1.8M	2.0M	1.4M	2.6M	2.6M	1.6M
Accumulated Other Comprehensive Income	(5.0M)	(5.0M)	(5.0M)	(5.2M)	(5.0M)	(4.8M)
Intangible Assets	12.7M	12.8M	12.4M	12.4M	14.3M	11.8M
Net Tangible Assets	32.8M	213.1M	186.7M	172.9M	198.8M	208.7M
Long Term Debt	1.9M	1.9M	1.8M	1.5M	1.7M	1.5M
Retained Earnings Total Equity	(116.9M)	(137.4M)	(186.4M)	(293.2M)	(337.1M)	(354.0M)
Capital Surpluse	170.2M	187.9M	417.3M	497.3M	571.9M	600.5M
Property Plant Equipment	1.1M	1.1M	1.4M	1.7M	1.9M	2.0M
Long Term Debt Total	1.9M	1.9M	1.8M	1.5M	1.7M	2.0M
Non Current Liabilities Other	2.8M	5.4M	1.5M	3.9M	4.2M	4.4M
Other Liab	3.1M	7.2M	330.5K	3.9M	4.5M	3.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC